

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/830,071
	Filing Date	April 23, 2004
	First Named Inventor	Gadde, Kishore M.
	Art Unit	1614
SHEET 1 OF 3	Examiner	Marschel, Ardin H. <i>R. Henley</i>
	Attorney Docket No.	OREX.009C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<i>[Signature]</i>	1	4,855,306	08-08-1989	Markstein, et al.	
	2	5,312,925	05-17-1994	Allen, et al.	
	3	5,403,595	04-01-1995	Kitchell, et al.	
	4	5,486,362	01-01-1996	Kitchell	
	5	6,150,366	11-21-2000	Arenson, et al.	
	6	6,197,827	03-01-2001	Cary	
	7	6,210,716	04-01-2001	Chen et al.	
	8	6,245,766 B1	06-12-2001	Watsky, Eric	
	9	6,248,363	06-19-2001	Mahesh, et al.	
	10	6,274,579	08-14-2001	Morgan et al.	
	11	6,686,337	02-03-2004	Gregory S. Connor	
	12	6,713,488	03-30-2004	Sadee, et al.	
	13	6,905,708	06-14-2005	Li, et al.	
	14	7,109,198	09-19-2006	Gadde, et al.	
	15	2002-0025972	2/28/2002	Hintz, Martin C.	
	16	2002-0037836	03-28-2002	Henriksen	
	17	2003-0144271	7-0-2003	Shulman	
	18	2004-0198668	10-07-2004	Gadde, et al.	
	19	2004-0242974	12-00-2004	Glover	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
<i>[Signature]</i>	20	WO 90/13294	11-15-1990	Whitby Research, Inc.		
	21	WO 04/050020	06-17-2004	Simon		
	22	WO 04/110368	12-23-2004	Merck & Co.		
	23	WO 04/110375	12-23-2004	Merck & Co.		
	24	WO 05/000217	01-06-2005	Merck & Co.		
	25	RU 2214241 (English abstract)	06-28-1996	Orto-MakneJL Farma's Jutikal, Ink		

Examiner Signature <i>[Signature]</i>	Date Considered <i>7/6/07</i>
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/830,071
	Filing Date	April 23, 2004
	First Named Inventor	Gadde, Kishore M.
	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Marschel, Ardin H. <i>R. Bentley</i>
SHEET 2 OF 3	Attorney Docket No.	OREX.009C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>RH</i>	26	Aronne, et al. "Weight Gain in the Treatment of Mood Disorders"; J Clin Psychiatry 2003;64 (supple 8)	
	27	Berke, et al., "Medical Management of Obesity", American Academy of Family Physicians, 2000 Jul 15;62(2):419-26 ABSTRACT	
	28	BLANCHARD, et al., "Pancreatitis Treated with Didanosine and Tenofabir Disoproxil Fumarate" Clinical Infectious Diseases, 2003;37 pgs 57-62	
	29	Carpenter, et al. "Mirtazapine Augmentation in the Treatment of Refractory Depression"; J Clin Psychiatry 60:1, January 1999	
	30	Cash, et al. "Attitudes about antidepressants: Influence of information about weight-related side effects"; Perceptual and Motor Skills, 2000, 90, 453-456	
	31	Deshmukh, et al. "Managing weight gain as a side effect of antidepressant therapy"; Cleveland Clinic Journal of Medicine Vol. 70, 7 July 2003	
	32	Fava, Maurizio. "Weight Gain and Antidepressants"; J Clin Psychiatry 2000;61 (suppl 11)	
	33	FUKAGAWA et al., "Monoaminergic anorectic agents", Nippon Yikurigaku Zasshi, 2001 Nov;118(5):303-8, 2001 ABSTRACT	
	34	Gehlert D.R., et al., "The Selective Norepinephrine Reuptake Inhibitor, LY368975, Reduces Food Consumption in Animal Models of Feeding", J. Pharmacology and Experimental Therapeutics 1998 Oct;287(1):122-7 ABSTRACT	
	35	Hashiguti, et al. "Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis"; Journal of Neural Transmission (1993) 93:213-223	
	36	Kanba et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18(4), 707-715 (1994)	
	37	Kossard, et al. Defining Urticarial Dermatitis; Arch Dermatol/Vol. 142, Jan 2006	
	38	Malhotra, et al., "Medical Management of Obesity Associated With Mental Disorders", Journal of Clinical Psychiatry 2002;63[suppl 4]:24-32	
	39	Michelson, et al., "Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study", Pediatrics 2001 Nov;108(5):E83 ABSTRACT	
	40	Okada, et al. "Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca ²⁺ dependent dopamine release" Epilepsy Research, 13 (1992) 113-119	
	41	Okada, et al. "Effects of zonisamide on dopaminergic system"; Epilepsy Research 22 (1995) 193-205	
	42	Olsen, et al., "Conjugate Addition Ligands of Opioid Antagonists. Methacrylate Esters and Ethers of 6Alpha- And 6Beta-Naltrexol", Journal of Medicinal Chemistry, American Chemical Society, vol. 33:2, 1990, 737-741	

Examiner Signature <i>R. Bentley</i>	Date Considered <i>7/6/07</i>
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/830,071
	Filing Date	April 23, 2004
	First Named Inventor	Gadde, Kishore M.
	Art Unit	1614
SHEET 3 OF 3	Examiner	Marschel, Ardin H. <i>R. Henley</i>
	Attorney Docket No.	OREX.009C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>JA</i>	43	Stromberg, et al., "A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats." Pharmacology, Biochemistry, and Behavior, vol. 72, 483-490 (2002)	
<i>JA</i>	44	Tollefson, et al., Am J. Psychiatry, 154(5), 457-465 (1997)	
<i>JA</i>	45	Wilner, "Is Weight Loss With Zonisamide Gender-Specific?", Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society	

3681907
042307

Examiner Signature <i>R. Henley</i>	Date Considered <i>7/6/07</i>
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.